Breaking News Instant updates and real-time market news.

CMCSA

Comcast

$45.74

-0.04 (-0.09%)

, CMCSK

Comcast

$0.00

(0.00%)

20:25
10/23/19
10/23
20:25
10/23/19
20:25

Notable companies reporting before tomorrow's open

Notable companies reporting before tomorrow's open, with earnings consensus, include Comcast (CMCSA), consensus 74c... Danaher (DHR), consensus $1.15... 3M Company (MMM), consensus $2.49... Northrop Grumman (NOC), consensus $4.77... Raytheon (RTN), consensus $2.86... Baxter International (BAX), consensus 84c... Dow Inc. (DOW), consensus 73c... Hershey (HSY), consensus $1.60... Twitter (TWTR), consensus 20c... Southwest Airlines (LUV), consensus $1.08... T. Rowe Price (TROW), consensus $1.98... Stanley Black & Decker (SWK), consensus $2.03... Huntington Bancshares (HBAN), consensus 33c... Citrix Systems (CTXS), consensus $1.25... Tractor Supply (TSCO), consensus $1.03.

CMCSA

Comcast

$45.74

-0.04 (-0.09%)

CMCSK

Comcast

$0.00

(0.00%)

DHR

Danaher

$138.39

1.19 (0.87%)

MMM

3M

$168.62

1.06 (0.63%)

NOC

Northrop Grumman

$352.89

0.48 (0.14%)

RTN

Raytheon

$203.81

-1.08 (-0.53%)

BAX

Baxter

$87.90

0.87 (1.00%)

DOW

Dow Inc.

$47.29

0.47 (1.00%)

HSY

Hershey

$149.67

-0.06 (-0.04%)

TWTR

Twitter

$38.83

0.01 (0.03%)

LUV

Southwest

$53.27

0.375 (0.71%)

TROW

T. Rowe Price

$108.01

0.01 (0.01%)

SWK

Stanley Black & Decker

$153.73

2.42 (1.60%)

HBAN

Huntington Bancshares

$14.49

0.06 (0.42%)

CTXS

Citrix

$103.60

-0.5 (-0.48%)

TSCO

Tractor Supply

$95.02

0.8 (0.85%)

  • 23

    Oct

  • 24

    Oct

  • 24

    Oct

  • 24

    Oct

  • 24

    Oct

  • 24

    Oct

  • 24

    Oct

  • 24

    Oct

  • 24

    Oct

  • 24

    Oct

  • 24

    Oct

  • 24

    Oct

  • 24

    Oct

  • 24

    Oct

  • 24

    Oct

  • 24

    Oct

  • 27

    Oct

  • 28

    Oct

  • 29

    Oct

  • 07

    Nov

  • 12

    Nov

  • 12

    Nov

  • 13

    Nov

  • 13

    Nov

  • 19

    Nov

  • 09

    Dec

  • 12

    Dec

CMCSA Comcast
$45.74

-0.04 (-0.09%)

10/16/19
10/16/19
INITIATION

Fly Intel: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. Verizon (VZ), Comcast (CMCSA), and AT&T (T) initiated with Market Perform ratings at Bernstein. 2. Inovalon (INOV) initiated with a Buy at Citi. 3. Assembly Biosciences (ASMB) initiated with a Buy at Mizuho. 4. ChromaDex (CDXC) initiated with an Outperform at Oppenheimer. 5. Axsome Therapeutics (AXSM) initiated with a Buy at Guggenheim. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
10/16/19
10/16/19
INITIATION
Target $50

Market Perform
Bernstein initiates Comcast with a Market Perform, awaits 'juicier pitch'
As previously reported, Bernstein analyst Peter Supino initiated coverage of Comcast with a Market Perform rating and $50 price target. Despite his bullishness on the Xfinity cable business, caution on NBCU's broadcast and cable network segments leave him waiting for a "juicier pitch" in Comcast.
10/15/19
BERN
10/15/19
INITIATION
Target $50
BERN
Market Perform
Comcast initiated with a Market Perform at Bernstein
Bernstein initiated Comcast with a Market Perform rating and $50 price target.
10/14/19
LEHM
10/14/19
NO CHANGE
Target $338
LEHM
Underweight
Barclays adjusts price targets in Cable, Satellite and Telecom Services
Cable sentiment remains positive going into Q3 earnings due to expectations of continued strength in unit and pricing growth, Barclays analyst Kannan Venkateshwar tells investors in a research note. While video trends could be weaker, the narrative around video "has flipped with investors starting to see this as a positive," according to Venkateshwar. The analyst believes these trends are likely to be supportive of shares in the near term, but he cautions against extrapolating them over the longer term. He increased his price target for Underweight-rated Charter Communications (CHTR) to $338 from $259, for Overweight-rated Comcast (CMCSA) to $48 from $45 and for Overweight-rated Altice USA (ATUS) to $33 from $30. Venkateshwar also lowered his price target for T-Mobile (TMUS to $88 from $93 and for Sprint (S) to $6 from $8 due to lower deal probability as a result of the states' lawsuit.
CMCSK Comcast
$0.00

(0.00%)

09/19/19
RSBL
09/19/19
NO CHANGE
Target $134
RSBL
Buy
Roku pullback an 'overreaction' to Comcast's free streaming box, says Rosenblatt
Rosenblatt analyst Mark Zgutowicz said yesterday's weakness in Roku (ROKU) shares was related to news that Comcast (CMSCA) will give its Xfinity Flex streaming box to its broadband only customers for free. However, he thinks the potential impact to Roku looks modest. He thinks Roku has a significant customer acquisition advantage via smart TV sell through, noting that Roku TV sales have represented an estimated 1 of 3 smart TVs sold this year. Zgutowicz maintains a Buy rating and $134 price target on Roku shares, which are down another 1% to $128.26 in pre-market trading.
07/29/19
FBCO
07/29/19
NO CHANGE
FBCO
Credit Suisse sees virtually no impact for AT&T, Verizon from Dish near-term
Following the Justice Department's settlement with T-Mobile (TMUS) and Sprint (S), Credit Suisse analyst Douglas Mitchelson notes that for Altice USA (ATUS), the settlement requires mobile virtual network operator contracts to be extended through at least 7 years post closing, which he views as a "significant positive" for Altice. For cable broadly, Dish (DISH) would represent an "intriguing option" for entry into the wireless business longer-term if CEO decided to sell the company, he contends. The analyst would expect that Comcast (CMCSA) and Charter (CHTR) would wait until the point where wireless pricing and valuations are thought to have bottomed. For AT&T (T) and Verizon (VZ), Mitchelson sees virtually no impact from Dish the next few years as the company will be just focused on scaling marketing of its T-Mobile MVNO while building its wireless network. Longer-term, while Dish might be in a position to deflate wireless pricing, AT&T and Verizon should still have superior coverage, network density, backhaul, scale, and quality of service, he adds.
09/25/19
BNCH
09/25/19
INITIATION
Target $64
BNCH
Buy
Comcast initiated with a Buy at Benchmark
Benchmark analyst Matthew Harrigan initiated Comcast with a Buy rating and $64 price target, citing his view that the company is uniquely positioned to benefit from fixed and wireless/mobile broadband growth, direct-to-consumer alternatives to traditional TV bundles and advanced advertising. He sees the potential at Comcast for low teens annual adjusted EPS growth, assuming resumed buyback activity in 2020, Harrigan said.
08/14/19
MACQ
08/14/19
DOWNGRADE
Target $31
MACQ
Neutral
Viacom downgraded to Neutral from Outperform at Macquarie
Macquarie analyst Tim Nollen downgraded Viacom (VIAB) to Neutral from Outperform and keeps a Neutral rating on CBS (CBS) shares after the two companies announced a merger deal with no premium for Viacom following "3 years of on again/off again merger discussions amidst wrenching change in the industry." While he believes the deal's strategic positives outweigh the risks, Nollen said integration might not be easy and that ViacomCBS will still be "small-ish" compared with competitors Comcast (CMCSA) and Disney (DIS). He lowered his price target on Viacom shares to $31 from $37 and cut his price target on CBS shares to $53 from $55.
DHR Danaher
$138.39

1.19 (0.87%)

10/14/19
MSCO
10/14/19
INITIATION
Target $29
MSCO
Equal Weight
Envista initiated with an Equal Weight at Morgan Stanley
Morgan Stanley analyst David Lewis initiated coverage of Envista (NVST), a spinoff of Danaher's (DHR) Dental segment, with an Equal Weight rating and $29 price target. Growth slowed from 2% to flat and margins compressed over the past three years as the company invested in innovation and while channel stabilization and new product launches provide a path to accelerate growth and expand margins, he thinks the stock's current valuation reflects some acceleration, Lewis tells investors.
10/14/19
JEFF
10/14/19
INITIATION
Target $34
JEFF
Buy
Envista initiated with a Buy at Jefferies
Jefferies analyst Brandon Couillard initiated coverage of Envista (NVST) with a Buy rating and $34 price target. Envista is emerging from a three-year turnaround inside Danaher (DHR) as a much stronger stand-alone company, well positioned for improved growth and margin expansion, Couillard tells investors in a research note. He finds the stock's current valuation as compelling.
10/14/19
FBCO
10/14/19
INITIATION
Target $151
FBCO
Outperform
Danaher reinstated with an Outperform at Credit Suisse
Credit Suisse analyst Erin Wilson Wright reinstated coverage of Danaher with an Outperform rating and $151 price target. The analyst likes the company's increasing exposure to "faster-growing" end markets like biopharma given its pending acquisition of GE's BioPharma business and the spin-off of Envista Holdings. Further, Danaher continues to expand its exposure to recurring revenue streams, adds the analyst.
09/23/19
SPIN
09/23/19
DOWNGRADE
SPIN
Hold
Danaher downgraded to Hold from Buy at Spin-Off Research
MMM 3M
$168.62

1.06 (0.63%)

07/26/19
FBCO
07/26/19
NO CHANGE
Target $194
FBCO
Outperform
3M price target raised to $194 from $180 at Credit Suisse
Credit Suisse analyst John Walsh raised his price target for 3M to $194 from $180 and maintained an Outperform rating following better than expected Q2 results. In a research note to investors, Walsh says he thinks the stock can grind higher given an organic sales growth inflection in the second half, on easing year ago comparisons coupled with market stabilization, which supports a 13X EV/EBITDA valuation. He cautions that environmental liabilities remain an overhang, with updates expected in the first quarter of 2020 and later in 2020.
09/12/19
JPMS
09/12/19
NO CHANGE
JPMS
Underweight
3M spoke to trends at lower end of guidance, says JPMorgan's Tusa
3M at a conference yesterday did not explicitly guide lower but spoke to trends at the low end of the range versus previous guidance, JPMorgan analyst Stephen Tusa tells investors in a research note. The analyst says the comments are in the direction of his below-consensus view, while noting they refer to results through August. Notably, 3M guided to somewhat softer Q3 organic and China growth, with the CFO citing "more macro uncertainty" in today's environment, says Tusa. Further, the analyst believes 3M's commentary on its business transformation also reinforces his point of a lack of visibility around benefits following high levels of spending, with returns on these initiatives seemingly "hard to discern." Tusa keeps an Underweight rating on 3M shares.
08/06/19
JPMS
08/06/19
NO CHANGE
Target $143
JPMS
Underweight
JPMorgan's Tusa cuts 3M target to $140, keeps Underweight on shares
JPMorgan analyst Stephen Tusa lowered his price target for 3M to $140 from $143 and keeps an Underweight rating on the shares. While headlines for the company's Q2 results "looked like a clear beat to low expectations," the internals of the quarter support a negative thesis, Tusa tells investors in a research note titled "The 'Model' Is Broken." 3M is "far from out of the woods" around its structural challenges, "which is an inability to grow both sales and margins, driven by a higher cost to serve the customer than in the past, unmasked when volumes decline," contends the analyst.
10/07/19
GUGG
10/07/19
DOWNGRADE
Target $200
GUGG
Neutral
Guggenheim downgrades Align Technology on rising competition, sinking sentiment
As previously reported, Guggenheim analyst Glen Santangelo downgraded Align Technology (ALGN) to Neutral from Buy with a price target of $200, down from $250. Santangelo now believes that competition is more aggressive than he originally anticipated after his proprietary channel checks suggested that the technical and service capabilities of the competition, while still "not nearly as good" as Align, may be evolving faster than expected. Many of the established dental companies - such as Dentsply Sirona (XRAY), 3M (MMM), Envista (NVST) and Henry Schein (HSIC) - are offering clear aligners at discounted prices and making a big push in this area, while the direct-to-consumer model has attracted significant attention in the wake of the recent SmileDirectClub (SDC) IPO, Santangelo stated. In all, his view is that sentiment on Align will likely remain challenged until investors fully understand the impact of the new competitive landscape, which may take until later in 2020.
NOC Northrop Grumman
$352.89

0.48 (0.14%)

08/06/19
MSCO
08/06/19
UPGRADE
Target $418
MSCO
Overweight
Northrop Grumman upgraded to Overweight from Equal Weight at Morgan Stanley
Morgan Stanley analyst Rajeev Lalwani upgraded Northrop Grumman to Overweight from Equal Weight and raised his price target for the shares to $418 from $335.
10/23/19
FBCO
10/23/19
NO CHANGE
Target $385
FBCO
Neutral
Lockheed Martin price target lowered to $385 from $401 at Credit Suisse
Credit Suisse analyst Robert Spingarn lowered his price target for Lockheed Martin (LMT) to $385 from $401 after quarterly results, while reiterating a Neutral rating on the shares. Although the analyst likes the stock, he remains on the sidelines as he relatively favors other defense names, particularly Northrop Grumman (NOC) and L3Harris Technologies (LHX).
08/06/19
08/06/19
UPGRADE

Fly Intel: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. Northrop Grumman (NOC) upgraded to Overweight from Equal Weight at Morgan Stanley with analyst Rajeev Lalwani citing his view that an opportunity for continued outperformance exists in Defense stocks. 2. Bancolombia (CIB) upgraded to Overweight from Neutral at JPMorgan and to Neutral from Underperform at Credit Suisse. 3. Ford (F) upgraded to Overweight from Equal Weight at Morgan Stanley with analyst Adam Jonas saying Ford's partnerships and "more focused" model lineup should keep its profitability "largely stable" through 2022. 4. Aimco (AIV) upgraded to Buy from Neutral at Mizuho with analyst Haendel St. Juste saying the company trades at a "two-turn multiple discount" to peers based on estimates 2020 funds from operations as well as a 10% discount to consensus net asset value versus peers' 2% premium. 5. EverQuote (EVER) upgraded to Outperform from Market Perform at Raymond James with analyst Aaron Kessler citing the company's "strong" Q2 results and outlook. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
08/06/19
MSCO
08/06/19
UPGRADE
Target $418
MSCO
Overweight
Northrop Grumman upgraded to Overweight with $418 target at Morgan Stanley
As previously reported, Morgan Stanley analyst Rajeev Lalwani upgraded Northrop Grumman (NOC) to Overweight from Equal Weight and raised his price target for the shares to $418 from $335, citing his view that an opportunity for continued outperformance exists in Defense stocks. Congress and the administration have both highlighted a need for continued investment in national security and the recently signed 2-year budget deal "effectively does away with the remaining sequestration budget caps," noted Lalwani. In that environment, he believes Northrop is well positioned given its longer duration capability and high-end technology focus. Lalwani, who also initiated coverage of L3Harris Technologies (LHX) with an Overweight rating and $259 price target this morning, contends that Northrop and L3Harris "stand out on multiple levels" from the other Defense Primes.
RTN Raytheon
$203.81

-1.08 (-0.53%)

10/03/19
FBCO
10/03/19
UPGRADE
Target $230
FBCO
Outperform
Credit Suisse upgrades Raytheon ahead of merger, boosts target to $230
Credit Suisse analyst Robert Spingarn upgraded Raytheon (RTN) to Outperform from Neutral and raised his price target for the shares to $230 from $188. The analyst believes United Technologies' (UTX) aerospace businesses are undervalued and that the market has yet to appropriately discount Raytheon's ~43.1% ownership of the proposed combined entity. Further, as standalone entity, Raytheon has very little net debt, which is a "significant positive" in the context of the pending merger with United Technologies' aerospace businesses, Spingarn tells investors in a research note.
10/03/19
10/03/19
UPGRADE

Fly Intel: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. Raytheon (RTN) upgraded to Outperform from Neutral at Credit Suisse WITH analyst Robert Spingarn saying he believes United Technologies' (UTX) aerospace businesses are undervalued and that the market has yet to appropriately discount Raytheon's ~43.1% ownership of the proposed combined entity. 2. Wipro (WIT) upgraded to Neutral from Sell at Goldman Sachs with analyst Sumeet Jain citing valuation. 3. Dova Pharmaceuticals (DOVA) upgraded to Neutral from Underweight at JPMorgan with analyst Joel Fishbein saying the company's "strong" execution continues to drive "impressive growth at scale" as customer deal sizes grow amid larger initial deployments and customers adopting multiple products. 4. Crowdstrike (CRWD) upgraded to Buy from Hold at SunTrust with analyst Joel Fishbein saying the company has developed a "category-defining" cloud platform for cyber security, a market that is "ripe for disruption." 5. Newmont Goldcorp (NEM) upgraded to Buy from Hold at Deutsche Bank with analyst Chris Terry saying shares of Newmont have significantly underperformed compared to its closest peer Barrick Gold (GOLD) and also versus the gold price. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
10/01/19
BOFA
10/01/19
NO CHANGE
BOFA
Top 10 US Ideas for Q4 at BofA/Merrill
BofA/Merrill introduced the Top 10 US Ideas for Q4 2019. The list's seven Buys are Aramark (ARMK), Salesforce (CRM), Disney (DIS), Dover (DOV), New York Community Bancorp (NYCB), Raytheon (RTN), and Target (TGT). Underperform's are Floor & Decor (FND), Gap (GPS), and Terex (TEX).
10/03/19
FBCO
10/03/19
UPGRADE
Target $230
FBCO
Outperform
Raytheon upgraded to Outperform from Neutral at Credit Suisse
Credit Suisse analyst Robert Spingarn upgraded Raytheon to Outperform from Neutral and raised his price target for the shares to $230 from $188.
BAX Baxter
$87.90

0.87 (1.00%)

09/10/19
PIPR
09/10/19
NO CHANGE
PIPR
Overweight
Baxter makes 'solid tuck-in' deal buying Cheetah Medical, says Piper Jaffray
After Baxter announced a deal to buy hemodynamic monitoring solutions maker Cheetah Medical for up to $230M in total consideration, Piper Jaffray analyst Matt O'Brien called the acquisition a "solid tuck-in" that presents significant cross-selling opportunities. Baxter continues to execute at a high level, according to O'Brien, who reiterated his Overweight rating on the stock.
07/26/19
FBCO
07/26/19
NO CHANGE
Target $95
FBCO
Outperform
Baxter price target raised to $95 from $84 at Credit Suisse
Credit Suisse analyst Matt Miksic raised his price target for Baxter to $95 from $84 and maintained an Outperform rating following the company's Q2 results, saying the results help shift the Med Delivery debate towards greater confidence in the 2019 6% growth target. Baxter's performance should help to reduce uncertainty on this issue and create more interest among investors, according to the analyst.
10/08/19
JPMS
10/08/19
NO CHANGE
Target $94
JPMS
Overweight
Baxter reiterated as top large-cap pick at JPMorgan
After spending time with management, JPMorgan analyst Robbie Marcus has a "high level of confidence" in Baxter International's ability to reach its 2020 long-range plan targets that call for accelerating sales growth and 200 basis points of operating margin expansion in 2020. The U.S. government's initiative to move dialysis patients into the home could double Baxter's ~$500M Peritoneal Dialysis business over the next few years, Marcus tells investors in a research note. The analyst also sees potential upside from the company's "unlevered" balance sheet. He reiterates Baxter as his top large-cap pick with an Overweight rating and $94 price target.
07/26/19
RAJA
07/26/19
NO CHANGE
Target $95
RAJA
Outperform
Baxter price target raised to $95 from $84 at Raymond James
Raymond James analyst Lawrence Keusch raised his price target on Baxter shares to $95 from $84 following a "solid" quarter marked by outperformance in its Advanced Surgery, Pharmaceuticals, and Medication Delivery segments. In particular, the recent momentum in Medication Delivery gives him increasing confidence in Baxter's ability to accelerate growth in the second half, said Keusch, who keeps an Outperform rating on the stock.
DOW Dow Inc.
$47.29

0.47 (1.00%)

07/31/19
07/31/19
DOWNGRADE

Fly Intel: Top five analyst downgrades
Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. AMD (AMD) downgraded to Hold from Buy at Craig-Hallum with analyst Christian Schwab citing the company's earnings and "disappointing" guidance for the third quarter that missed both his and Street expectations due to lower than anticipated Semicustom revenue expectations. 2. Dow Inc. (DOW) downgraded to Outperform from Top Pick at RBC Capital with analyst Arun Viswanathan citing the "compression in the PU/siloxanes earnings" as well as softer macro conditions. 3. Total (TOT) downgraded to Equal Weight from Overweight at Morgan Stanley. 4. Broadridge (BR) downgraded to Market Perform from Outperform at Raymond James with analyst Patrick O'Shaughnessy saying the risk/reward is balanced at current share levels. 5. T2 Biosystems (TTOO) downgraded to Neutral from Overweight at Cantor Fitzgerald and to Neutral from Buy at Janney Montgomery Scott and H.C. Wainwright. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
08/16/19
BOFA
08/16/19
DOWNGRADE
BOFA
Underperform
Dow Inc. downgraded to Underperform from Neutral at BofA/Merrill
08/16/19
BOFA
08/16/19
NO CHANGE
BOFA
BofA/Merrill shakes up ratings in chemicals space with 2 upgrades, 4 downgrades
BofA Merrill Lynch analyst Steve Byrne said it appears that risks of U.S. economic contagion from the broader global macro slowdown are "steadily building." Given this view, he has generally moved to be more cautious on the earnings outlook and ratings for stocks with global industrial exposure, resulting in his upgrade of two chemicals stocks and his downgrades of four others. Byrne downgraded Dow Inc. (DOW) to Underperform from Neutral and Westlake Chemical (WLK) to Underperform from Buy, noting their commodity exposure. He downgraded Axalta Coating (AXTA) to Neutral from Buy and cut PPG (PPG) to Underperform from Neutral as he is getting more cautious about their revenue prospects. He upgraded Venator Materials (VNTR) to Buy from Underperform, citing what he views as an attractive risk-reward as he expects earnings will grow in 2020, driven by product upgrades and productivity initiatives. Byrne also upgraded Nutrien (NTR) to Neutral from Underperform as he believes Ag stocks could prove to be defensive plays.
10/11/19
RHCO
10/11/19
NO CHANGE
Target $108
RHCO
Hold
SunTrust sees 'lackluster' September quarter results from chemical companies
SunTrust analyst James Sheehan tells investors in a research note that he expects chemical companies to report in-line to below-consensus Q3 results driven by the trade war, slowing GDP in Europe, weak automotive and manufacturing end markets, loosening supply/demand for certain commodity product chains and FX headwinds. Looking ahead, the analyst sees "cautious" commentary for Q4 given the lack of end market acceleration and continued USD strength. The analyst lowered his price target for Chemours (CC) to $16 from $14, for Dow Inc (DOW) to $46 from $52, for Corteva (CTVA) to $28 from $30, for DuPont (DD) to $68 from $75, for Eastman Chemical (EMN) to $75 from $80, for Element Solutions (ESI) to $10 from $11, for Kraton (KRA) to $24 from $33 and for Kronos Worldwide (KRO) to $12 from $13. Sheehan raised his price target for Celanese (CE) to $120 from $108.
HSY Hershey
$149.67

-0.06 (-0.04%)

09/12/19
BERN
09/12/19
DOWNGRADE
BERN
Market Perform
Hershey downgraded to Market Perform from Outperform at Bernstein
10/17/19
RBCM
10/17/19
INITIATION
Target $158
RBCM
Sector Perform
Hershey resumed with a Sector Perform at RBC Capital
RBC Capital analyst Nik Modi resumed Hershey with a Sector Perform rating and a price target of $158 as part of his broader research note initiating the Packaged Foods sector. The analyst is positive on the company's improved revenue trajectory due to a "more rational pricing environment", he is concerned with tightening competition "outside Hershey's traditional peer set". Modi adds that while Hershey is looking to improve its execution with investments in technology and human capital, the innovation may not be sufficient for it gain market share.
07/26/19
BMOC
07/26/19
NO CHANGE
Target $133
BMOC
Market Perform
Hershey price target raised to $133 from $108 at BMO Capital
BMO Capital analyst Kenneth Zaslow raised his price target on Hershey to $133 after its second consecutive quarter of earnings outperformance. The analyst also keeps his Market Perform rating, saying that despite the beat, the management kept the upper end of its FY19 outlook on the likelihood of a "muted benefit" from its recent price increase.
09/12/19
09/12/19
DOWNGRADE
Target $155

Market Perform
Hershey downgraded to Market Perform on valuation at Bernstein
As previously reported, Bernstein analyst Alexia Howard downgraded Hershey to Market Perform from Outperform, while keeping her $155 price target on the shares. Although the analyst believes that Hershey will continue to enjoy margin improvement and low-single-digit top line growth, she now thinks the benefits of improved input costs and upcoming price increases have largely been recognized by the market.
TWTR Twitter
$38.83

0.01 (0.03%)

10/23/19
BMOC
10/23/19
NO CHANGE
Target $45
BMOC
Market Perform
Twitter price target raised to $45 from $42 at BMO Capital
BMO Capital analyst Daniel Salmon raised his price target on Twitter to $45 ahead of its Q3 results to reflect his view of a "strong" advertising market and a low probability of a 2019 recession. The analyst also cites his outlook of acceleration in Twitter's "DR ad business", but keeps his Market Perform rating on the stock given the "balanced" risk-reward in its valuation and the expectations of the management's continued investment.
10/17/19
MKMP
10/17/19
INITIATION
Target $44
MKMP
Neutral
MKM assumes Twitter at Neutral, says wait for better entry point
MKM Partners analyst Rohit Kulkarni assumed coverage of Twitter with a Neutral rating and $44 price target. The company's turnaround is "still in its early innings" as its active user base has stabilized and started to grow again, Kulkarni tells investors in a research note. However, with the shares up 40% year-to-date, the analyst prefers to wait for a better entry. He says tougher upcoming comps and elevated expectations keep him on the sidelines for now. MKM had a Buy rating on Twitter before stopping coverage of the name in 2018.
10/17/19
MKMP
10/17/19
INITIATION
Target $44
MKMP
Twitter assumed with a Neutral at MKM Partners
MKM Partners analyst Rohit Kulkarni assumed coverage of Twitter with a Neutral rating and $44 price target.
10/22/19
KEYB
10/22/19
NO CHANGE
KEYB
Ad spending across major internet platforms remained healthy in Q3, says KeyBanc
KeyBanc analyst Andy Hargreaves says that despite signs of softness from large ad agencies, he believes ad spending across the major internet platforms remained healthy in Q3. The analyst expects positive results out of Facebook (FB) and results from Alphabet (GOOGL) that are largely in line with expectations. Feedback was more mixed around Twitter (TWTR), but not consistent enough to prompt a change to his estimates. Hargreaves continues to recommend owning Alphabet and Facebook.
LUV Southwest
$53.27

0.375 (0.71%)

10/21/19
STFL
10/21/19
DOWNGRADE
STFL
Hold
Southwest downgraded to Hold from Buy at Stifel
10/21/19
STFL
10/21/19
DOWNGRADE
Target $60
STFL
Hold
Stifel downgrades Southwest on risk of deal to lessen Boeing dependency
Stifel analyst Joseph DeNardi downgraded Southwest Airlines (LUV) to Hold from Buy with a price target of $60, down from $75. The stock in morning trading is up 7c to $53.55. Southwest is an all Boeing (BA) 737 airline, which makes its business model dependent on 737s, DeNardi tells investors in a research note. Southwest's decision to remove the 737 MAX from its schedule through early February, a "deteriorating" relationship between the Federal Aviation Administration and Boeing, and reports that Boeing may be looking at a 737 MAX rate cut indicate that Southwest "may be nearing a tipping point" where the duration of the MAX grounding pushes it to consider more significant and strategic solutions, including acquisitions, DeNardi contends. The analyst believes an acquisition by Southwest motivated by a desire to diversify away from the MAX "creates significant risks" in the near term for the company. DeNardi today also upgraded shares of JetBlue Airways (JBLU) to Buy from Hold.
10/21/19
STFL
10/21/19
UPGRADE
Target $24
STFL
Buy
JetBlue could be worth $28 in a takeout scenario, says Stifel
Stifel analyst Joseph DeNardi upgraded JetBlue to Buy from Hold with a price target of $24, up from $22. In a research note to investors, DeNardi says that a prolonged grounding of Boeing's (BA) 737 MAX is an "existential threat" to Southwest's (LUV) business model and that the "only reasonable option" Southwest has to address this risk is through an acquisition of JetBlue or Alaska Air (ALK). When combined with JetBlue's attractive CASMx story into 2020, the analyst now sees the increased likelihood of M&A as presenting a sufficiently attractive risk/reward setup to justify an upgrade. JetBlue could be worth $28 in a takeout scenario, DeNardi says. The Stifel analyst downgraded Southwest to Hold from Buy.
09/13/19
MACQ
09/13/19
UPGRADE
Target $67
MACQ
Outperform
Southwest upgraded to Outperform from Neutral at Macquarie
Macquarie analyst Susan Donofrio upgraded Southwest to Outperform from Neutral and raised her price target on the shares to $67 from $52.
TROW T. Rowe Price
$108.01

0.01 (0.01%)

10/07/19
BMOC
10/07/19
INITIATION
BMOC
KKR, Victory Capital, Apollo Global top BMO Capital picks among asset managers
BMO Capital analyst James Fotheringham initiated 11 U.S. asset managers, selecting KKR (KKR), Victory Capital (VCTR), and Apollo Global (APO) as his "top picks" with Outperform ratings and respective price targets of $40, $33, and $52 per share. The analyst believes that investors are undervaluing KKR's performance fees reliability and also have yet to appropriately value its "meaningful" excess capital. Instead, Fotheringham believes that investors are too worried about the risks of recession and KKR's relatively larger balance sheet. For Victory Global, the analyst believes that the market is overly concerned with its balance sheet leverage and believes that the company's organic growth will outperform expectations because of its exposure to to higher-growth segments like ETF products and solutions-seeking investors. For Apollo Global, Fotheringham notes that investors are undervaluing its accelerating Fee Related Earnings growth and expects the stock to benefit from technical support related to "improved liquidity, broadened shareholder engagement, and index inclusions." As part of his research note, the analyst also started the following at Market Perform: Ares Management (ARES) with price target $31, Invesco (IVZ) with price target $18, Blackrock (BLK) with price target $44, AssetMark (AMK) with price target $24, Blackstone (BX) with price target of $44, Carlyle Group (CG) with price target of $23, and T. Rowe Price (TROW) with price target of $101. Fotheringham also initiated Franklin Resources (BEN) at Underperform with price target of $16, saying the market is overvaluing its management-fee related income amid continued outflows and magnified redemption risk as well as operating expense "inflexibility". The analyst warns that Franklin's U.S. and European retail channels are facing ongoing fee pressures and risk from active-to-passive rotation.
10/07/19
BMOC
10/07/19
INITIATION
BMOC
Market Perform
T. Rowe Price initiated with a Market Perform at BMO Capital
07/09/19
MSCO
07/09/19
NO CHANGE
MSCO
Morgan Stanley sees C-corp conversion announcement coming from Carlyle
Morgan Stanley analyst Michael Cyprys said he recommends owning Carlyle Group (CG) shares into the quarter, as he believes the company will announce plans to convert to a C-corporation along with its upcoming report, "albeit with a delayed effective date" to allow time for the complex underlying tax impact analysis. He thinks a conversion could bring greater clarity and visibility into targets, which could increase long only interest in the stock, Cyprys tells investors. In his broader preview of the earnings season for the Asset Manager group, the analyst noted that he lowered his Q2 EPS estimates by about 4% on average, cutting his estimates for Traditionals by 0.5%, for Alts by 11.5% and for Market Structure companies by 1.6%.
09/18/19
MSCO
09/18/19
NO CHANGE
Target $553
MSCO
Overweight
BlackRock's 'extreme' recent underperformance overdone, says Morgan Stanley
Morgan Stanley analyst Michael Cyprys noted that BlackRock (BLK) shares are down 8% in the last 60 days and the stock has underperformed T. Rowe Price (TROW) shares by 14% points over that time, which he views as "extreme" and calls out as the most significant relative underperformance seen over the past 5 years. In the only other two other examples of similar underperformance he can identify, BlackRock shares recovered "a few hundred basis points" in the subsequent days and weeks, noted Cyprys, who views the recent weakness in the stock as a "compelling tactical buying opportunity." The analyst, who thinks the long-term fundamentals and business growth are intact at BlackRock, keeps an Overweight rating on the shares with a $553 price target.
SWK Stanley Black & Decker
$153.73

2.42 (1.60%)

09/17/19
KEYB
09/17/19
DOWNGRADE
KEYB
Sector Weight
Stanley Black & Decker downgraded to Sector Weight from Overweight at KeyBanc
09/18/19
KEYB
09/18/19
DOWNGRADE
KEYB
Sector Weight
Stanley Black & Decker downgraded to Sector Weight from Overweight at KeyBanc
KeyBanc analyst Kenneth Zener last night downgraded Stanley Black & Decker to Sector Weight from Overweight without a price target. The analyst has taken a more selective posture on the household appliances space "as macro catalysts wane." Further, he sees limited valuation upside as "earnings momentum weakens." Stanley's upside catalysts of tool share gains and rising margins are balanced by downside catalysts of slowing industrial indicators and weaker non-U.S. trends, Zener tells investors in a research note. He awaits an upward earnings catalyst to get constructive on Stanley Black & Decker shares.
07/24/19
GABE
07/24/19
DOWNGRADE
GABE
Hold
Gabelli downgrades Stanley Black & Decker to Hold on valuation
As previously reported, Gabelli analyst Justin Bergner downgraded Stanley Black & Decker (SWK) to Hold from Buy, citing valuation following the stock's recent outperformance compared to the Industrial Select Sector SPDR (XLI). Normalized free cash flow conversion "suggests [Stanley] is not as cheap as P/E would suggest," added Bergner.
09/26/19
JPMS
09/26/19
UPGRADE
Target $172
JPMS
Overweight
JPMorgan upgrades Whirlpool to Overweight, boosts price target to $172
JPMorgan analyst Michael Rehaut upgraded Whirlpool (WHR) to Overweight from Neutral and raised his price target for the shares to $172 from $155. The analyst expects U.S. industry shipments to be more stable year-over-year through the end of 2019 and show "modest" growth in 2020. Further, he thinks point to steel prices will remain "at bay" and that Whirlpool's European operations will "finally" turn a small profit in the second half of 2019. In addition, Rehaut views the stock's valuation as inexpensive. The analyst this morning also downgraded Beacon Roofing Supply (BECN) to Underweight from Neutral. His top picks in the Building Products sector remain Stanley Black & Decker (SWK) and Fortune Brands (FBHS).
HBAN Huntington Bancshares
$14.49

0.06 (0.42%)

09/24/19
MSCO
09/24/19
NO CHANGE
MSCO
Large-cap banks aren't gaining deposit market share, says Morgan Stanley
Morgan Stanley analyst Ken Zerbe said he continues to hear the "false narrative" that large-cap banks must be gaining market share due to their superior technology, but he insists they are not and that small and mid-cap banks have consistently gained deposit market share over the last five years. Individual large-cap banks that have had the biggest deposit share gains include Goldman Sachs (GS), Ally Financial (ALLY) and Synchrony Financial (SYF), while mid-cap banks that have delivered the biggest gains in share of total deposits include First Republic (FRC), KeyCorp (KEY) and Huntington (HBAN), Zerbe tells investors. Large-cap banks that have seen the largest declines in their respective individual shares of total deposits include JPMorgan (JPM), Wells Fargo (WFC) and Citigroup (C), while deposit share losers among mid-cap banks include Comerica (CMA), Prosperity Bancshares (PB) and Zions (ZION), said Zerbe.
09/13/19
DADA
09/13/19
DOWNGRADE
DADA
Neutral
Huntington Bancshares downgraded to Neutral from Buy at DA Davidson
09/13/19
DADA
09/13/19
DOWNGRADE
Target $16
DADA
Neutral
Huntington Bancshares downgraded to Neutral at DA Davidson on valuation
DA Davidson analyst Kevin Reevey downgraded Huntington Bancshares to Neutral with an unchanged price target of $16, saying that after a 22.9% rise in its stock price year-to-date and 32% from its 52-week low, the stock is now trading at 9.5% premium to its peers with an earnings multiple of 10.5-times his expected FY20 earnings. The analyst notes that the bank's balance sheet is well positioned for a lower interest rate environment and its capital return story remains "solidly intact", but he sees the recent run-up in the stock price creating a profit taking opportunity.
09/13/19
09/13/19
DOWNGRADE

Fly Intel: Top five analyst downgrades
Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. O'Reilly Automotive (ORLY) downgraded to Neutral from Buy at Citi with analyst Gregory Badishkanian stating he views O'Reilly as a "best-in-class operator" but is on the sidelines due to valuation. 2. Legg Mason (LM) downgraded to Market Perform from Outperform at Wells Fargo with analyst Christopher Harris saying he believes "substantial value" in Legg Mason has now been unlocked following the implementation of an aggressive cost savings plan and the stock's "meaningful" outperformance year-to-date. 3. Cboe Global Markets (CBOE) downgraded to Underperform from Buy at BofA/Merrill with analyst Michael Carrier noting trends have moderated some in September while its compares in Q4 are tough. 4. Huntington Bancshares (HBAN) downgraded to Neutral from Buy at DA Davidson with analyst Kevin Reevey saying that after a 22.9% rise in its stock price year-to-date and 32% from its 52-week low, the stock is now trading at 9.5% premium to its peers with an earnings multiple of 10.5-times his expected FY20 earnings. 5. Broadcom (AVGO) downgraded to Hold from Buy at Loop Capital with analyst Cody Acree noting that the company met expectations for Q3, but management has warned about the "very low-growth environment" expected for the foreseeable future unless the macro backdrop improves. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
CTXS Citrix
$103.60

-0.5 (-0.48%)

06/06/19
DBAB
06/06/19
UPGRADE
Target $120
DBAB
Buy
Deutsche Bank upgrades Citrix on 'under the radar' desktop strength
Deutsche Bank analyst Karl Keirstead upgraded Citrix Systems to Buy from Hold and raised his price target for the shares to $120 from $110. The analyst sees strength in the company's desktop business. The unit grew 13% in Q1 and growth is projected at 5%-9% going forward despite the "weight of an ongoing transition to a subscription and cloud model," Keirstead tells investors in a research note. He believes this growth is "under the radar" given Citrix's current low valuation.
07/25/19
JEFF
07/25/19
NO CHANGE
Target $85
JEFF
Underperform
Citrix shares remain overvalued after Q2 miss, says Jefferies
Citrix reported Q2 results that were below consensus estimates and guidance, issued Q3 guidance below expectations and lowered its guidance for the year, Jefferies analyst John DiFucci tells investors in a post-earnings research note. While the lowered numbers were attributed to an accelerated move to subscription, but deferred revenue was also below expectations, which doesn't support this conclusion, says the analyst. DiFucci continues to believe Citrix shares are overvalued and he keeps an Underperform rating on the name with an $85 price target.
10/08/19
JEFF
10/08/19
INITIATION
Target $80
JEFF
Underperform
Citrix assumed with an Underperform rating at Jefferies
Jefferies analyst Brent Thill assumed coverage of Citrix with an Underperform rating with a price target of $80, down from $85. The analyst last night assumed coverage of the Software industry and adjusted some of his ratings to be more defensive in light of valuation and macroeconomic concerns. However, he remains positive on the industry and believes that the fundamentals of businesses in the space are "very strong."
07/25/19
STFL
07/25/19
NO CHANGE
Target $100
STFL
Hold
Faster than expected subscription transition pressuring Citrix, says Stifel
Stifel analyst Brad Reback noted that an accelerating subscription transition drove Citrix's Q2 miss and prompted the company to lower its FY19 top and bottom-line guidance. He keeps a Hold rating on the stock and lowered his price target on Citrix shares to $100 from $115 given the elevated operational and financial headwinds he sees being associated with the company's subscription-model transition.
TSCO Tractor Supply
$95.02

0.8 (0.85%)

10/23/19
BARD
10/23/19
NO CHANGE
Target $120
BARD
Outperform
Tractor Supply price target lowered to $120 from $125 at Baird
Baird analyst Peter Benedict lowered his price target on Tractor Supply to $120 from $125 ahead of Q3 results. The analyst noted the shares have lagged the market over the past three months so an earnings miss may be anticipated at this point. He said there are multiple initiatives in place to sustain profitable market share gains for years to come and the underlying risk/reward looks favorable at current levels. Benedict maintained his Outperform rating on Tractor Supply shares.
10/07/19
RAJA
10/07/19
INITIATION
Target $115
RAJA
Strong Buy
Tractor Supply resumed with a Strong Buy at Raymond James
Raymond James analyst Matthew McClintock resumed coverage of Tractor Supply with a Strong Buy rating and a price target of $115. The analyst contends that the company can generate an earnings growth rate of at least 10% per year while expanding its EBIT margins by about 20bps. McClintock is also positive on Tractor Supply's "solid" dividend yield, which he sees as "rare" for a growth retailer, as well as its dominant position in a "fairly isolated" niche part of the retail industry.
10/08/19
WOLF
10/08/19
INITIATION
Target $95
WOLF
Peer Perform
Tractor Supply assumed with a Peer Perform rating at Wolfe Research
Wolfe Research analyst Chris Bottiglieri assumed coverage of Tractor Supply with a Peer Perform rating and $95 price target.
10/14/19
WELS
10/14/19
NO CHANGE
Target $115
WELS
Outperform
Tractor Supply price target lowered to $115 from $125 at Wells Fargo
Wells Fargo analyst Zachary Fadem lowered his price target for Tractor Supply to $115 from $125, while reiterating an Outperform rating on the shares. The analyst notes that sentiment has shifted deeply negative, but he sees relief rally potential. While investors have turned more cautious, Fadem continues to favor Tractor Supply's defensive, staples-like characteristics, longer-term growth levers and investment-driven improvement potential versus a highly fragmented and under-invested peer set.

TODAY'S FREE FLY STORIES

CWK

Cushman & Wakefield

$19.10

0.1 (0.53%)

17:48
11/15/19
11/15
17:48
11/15/19
17:48
Hot Stocks
Cushman & Wakefield CEO sells 84.6K share of common stock »

In a regulatory filing,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 12

    Nov

LMT

Lockheed Martin

$393.52

3.305 (0.85%)

17:39
11/15/19
11/15
17:39
11/15/19
17:39
Hot Stocks
Lockheed Martin awarded maximum $3.33B Air Force contract »

Lockheed Martin has been…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ESCA

Escalade

$10.90

-0.09 (-0.82%)

17:38
11/15/19
11/15
17:38
11/15/19
17:38
Hot Stocks
Escalade CEO Fetherman to retire »

Escalade announced that…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CZR

Caesars

$12.96

0.1 (0.78%)

, ERI

Eldorado Resorts

$52.10

0.93 (1.82%)

17:38
11/15/19
11/15
17:38
11/15/19
17:38
Hot Stocks
Eldorado, Caesars stockholders approve Eldorado acquisition of Caesars »

Eldorado Resorts (ERI)…

CZR

Caesars

$12.96

0.1 (0.78%)

ERI

Eldorado Resorts

$52.10

0.93 (1.82%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 15

    Nov

EGRX

Eagle Pharmaceuticals

$57.24

0.55 (0.97%)

17:15
11/15/19
11/15
17:15
11/15/19
17:15
Syndicate
Breaking Syndicate news story on Eagle Pharmaceuticals »

Eagle Pharmaceuticals…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

FN

Fabrinet

$60.82

0.84 (1.40%)

17:11
11/15/19
11/15
17:11
11/15/19
17:11
Hot Stocks
Fabrinet President Gill sells 12.9K shares of common stock »

In a regulatory filing,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 12

    Dec

TEUM

Pareteum

$0.38

-0.0209 (-5.21%)

17:05
11/15/19
11/15
17:05
11/15/19
17:05
Hot Stocks
Pareteum receives noncompliance notice from Nasdaq »

Pareteum announced that…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

HEXO

Hexo

$1.78

-0.1 (-5.32%)

17:00
11/15/19
11/15
17:00
11/15/19
17:00
Hot Stocks
Hexo was cannabis was being grown in unlicensed space at Niagara site »

HEXO Corp provided…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AMGN

Amgen

$220.84

2.29 (1.05%)

, CELG

Celgene

$110.02

-0.01 (-0.01%)

16:57
11/15/19
11/15
16:57
11/15/19
16:57
Hot Stocks
Bristol-Myers gets FTC clearance for Celgene acquisition »

Bristol-Myers Squibb…

AMGN

Amgen

$220.84

2.29 (1.05%)

CELG

Celgene

$110.02

-0.01 (-0.01%)

BMY

Bristol-Myers

$58.61

0.11 (0.19%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Nov

  • 04

    Dec

  • 07

    Dec

  • 25

    Mar

  • 04

    Apr

RAVE

Rave Restaurant

$1.44

-0.79 (-35.43%)

16:47
11/15/19
11/15
16:47
11/15/19
16:47
Hot Stocks
BBRC Asset Management reports 6.6% passive stake in Rave Restaurant »

BBRC Asset Management …

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CHAP

Chaparral Energy

$0.89

-0.0521 (-5.52%)

16:46
11/15/19
11/15
16:46
11/15/19
16:46
Hot Stocks
Chaparral Energy receives continued listing standard notice from NYSE »

Chaparral Energy…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

16:45
11/15/19
11/15
16:45
11/15/19
16:45
General news
Breaking General news story  »

San Francisco Federal…

16:45
11/15/19
11/15
16:45
11/15/19
16:45
General news
Breaking General news story  »

San Francisco Federal…

CI

Cigna

$196.08

6.41 (3.38%)

, CNC

Centene

$57.57

2.91 (5.32%)

16:41
11/15/19
11/15
16:41
11/15/19
16:41
On The Fly
Fly Intel: Wall Street's top stories for Friday »

Stocks closed out the…

CI

Cigna

$196.08

6.41 (3.38%)

CNC

Centene

$57.57

2.91 (5.32%)

CVS

CVS Health

$74.27

1.34 (1.84%)

HUM

Humana

$335.43

17.48 (5.50%)

UNH

UnitedHealth

$269.44

13.68 (5.35%)

WCG

WellCare

$312.01

10.155 (3.36%)

HNT

Health Net

$0.00

(0.00%)

MOH

Molina Healthcare

$129.60

7.3 (5.97%)

ANTM

Anthem

$298.18

16.14 (5.72%)

HCA

HCA Healthcare

$137.98

3.51 (2.61%)

CYH

Community Health

$3.12

0.25 (8.71%)

LPNT

LifePoint

$0.00

(0.00%)

UHS

Universal Health

$144.30

3.13 (2.22%)

NVDA

Nvidia

$204.12

-5.76 (-2.74%)

AMZN

Amazon.com

$1,739.33

-15.38 (-0.88%)

MSFT

Microsoft

$149.95

1.89 (1.28%)

UAA

Under Armour

$17.78

0.65 (3.79%)

UA

Under Armour

$15.97

0.41 (2.64%)

AMRN

Amarin

$23.99

2.5 (11.63%)

JNJ

Johnson & Johnson

$134.97

3.99 (3.05%)

GOOG

Alphabet

$1,334.01

21.82 (1.66%)

GOOGL

Alphabet Class A

$1,333.33

23.54 (1.80%)

ORCL

Oracle

$56.43

0.33 (0.59%)

RH

RH

$188.73

13.535 (7.73%)

QGEN

Qiagen

$40.56

3.255 (8.73%)

FTCH

Farfetch

$9.66

2.17 (28.97%)

THC

Tenet

$30.55

1.08 (3.66%)

TORC

resTORbio

$1.10

-6.83 (-86.13%)

ACB

Aurora Cannabis

$2.72

-0.57 (-17.33%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 15

    Nov

  • 19

    Nov

  • 19

    Nov

  • 20

    Nov

  • 20

    Nov

  • 20

    Nov

  • 22

    Nov

  • 04

    Dec

  • 07

    Dec

  • 09

    Dec

  • 09

    Dec

  • 13

    Dec

  • 28

    Dec

  • 06

    Jan

  • 21

    Jan

  • 06

    Feb

NYT

New York Times

$31.60

0.44 (1.41%)

16:41
11/15/19
11/15
16:41
11/15/19
16:41
Hot Stocks
New York Times CEO sells 66,000 class A common shares »

In a regulatory filing,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 09

    Dec

WEX

Wex

$200.52

4.61 (2.35%)

16:41
11/15/19
11/15
16:41
11/15/19
16:41
Hot Stocks
Wex director Morris sells 3K shares of common stock »

In a regulatory filing,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CBLI

Cleveland BioLabs

$0.59

-0.0444 (-6.97%)

16:39
11/15/19
11/15
16:39
11/15/19
16:39
Hot Stocks
Cleveland BioLabs CEO resigns effective December 13th »

In a regulatory 8-K…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

LOGC

LogicBio Therapeutics

$9.29

-0.04 (-0.43%)

16:38
11/15/19
11/15
16:38
11/15/19
16:38
Syndicate
Breaking Syndicate news story on LogicBio Therapeutics »

LogicBio Therapeutics…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

HTBI

HomeTrust

$25.99

-0.31 (-1.18%)

16:38
11/15/19
11/15
16:38
11/15/19
16:38
Hot Stocks
HomeTrust raises quarterly dividend 17% to 7c per share »

HomeTrust Bancshares…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Nov

FR

First Industrial Realty

$42.05

-0.03 (-0.07%)

16:36
11/15/19
11/15
16:36
11/15/19
16:36
Hot Stocks
First Industrial Realty director sells 12K shares of common stock »

In a regulatory filing,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

UBSI

United Bankshares

$39.51

-0.19 (-0.48%)

16:31
11/15/19
11/15
16:31
11/15/19
16:31
Hot Stocks
United Bankshares declares Q4 dividend of 35c per share »

United Bankshares…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

16:30
11/15/19
11/15
16:30
11/15/19
16:30
Options
Preliminary option volume of 24.0M today »

Preliminary option volume…

16:25
11/15/19
11/15
16:25
11/15/19
16:25
Conference/Events
Federal Reserve Bank of San Francisco participates in a discussion »

San Francisco Federal…

GNLN

Greenlane

$3.36

-0.05 (-1.47%)

16:23
11/15/19
11/15
16:23
11/15/19
16:23
Hot Stocks
Greenlane CEO buys 56.4K shares of common stock »

In a regulatory filing,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AJG

Arthur J. Gallagher

$91.89

-0.42 (-0.45%)

16:20
11/15/19
11/15
16:20
11/15/19
16:20
Syndicate
Breaking Syndicate news story on Arthur J. Gallagher »

Arthur J. Gallagher files…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.